이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

절제 불가능한 결장직장 간 전이가 있는 환자를 위한 치료 표준 화학 요법과 단독 치료 화학 요법에 펌프 화학 요법을 테스트: PUMP 시험

2026년 9월 21일 업데이트: ECOG-ACRIN Cancer Research Group

절제 불가능한 결장직장 간 전이에 대한 간동맥 주입 유무에 따른 전신 요법의 무작위 3상 연구: PUMP 시험

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVE:

I. To determine if patients with persistently unresectable colorectal liver metastases (CRLM) after treatment with first-line chemotherapy have improved overall survival (OS) with hepatic arterial infusion (HAI) and systemic chemotherapy versus systemic chemotherapy alone.

SECONDARY OBJECTIVES:

I. To determine whether there is a direct association between hepatic progression free survival (hPFS) and overall survival (OS) when patients are treated with HAI combined with systemic chemotherapy for unresectable CRLM.

II To determine the impact on progression free survival (overall, hepatic and extrahepatic) for patients with unresectable CRLM treated with HAI in combination with systemic chemotherapy.

III. To determine objective response rate (ORR) in the liver, defined as the proportion of patients achieving complete or partial response by Response Evaluation Criteria is Solid Tumors (RECIST) 1.1.

IV. To determine the rate of conversion to resectable disease, defined as the proportion of patients who successfully convert from unresectable to resectable status and undergo R0/R1 resection/ablation.

V. To determine the rate in which patients are intended to be treated with HAI but are deemed ineligible at the time of planned pump insertion due to detection of occult extrahepatic disease or unsuitable arterial anatomy (Intra-Operative Ineligibility, IOI).

VI. To determine the extent to which patient and disease-specific factors correlate with short- and long-term risk of HAI-specific complications.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo surgery to place the HAI pump within 6 weeks of randomization, followed by single photon emission computed tomography/computed tomography (SPECT/CT) on study. Patients then receive floxuridine via the HAI pump within 12 weeks of randomization on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician within 16 weeks of randomization: FOLFOX (fluorouracil intravenously [IV], oxaliplatin IV, and leucovorin IV), FOLFIRI (fluorouracil IV, irinotecan IV, and leucovorin IV), or OX/IRI (oxaliplatin IV and irinotecan IV) with or without cetuximab IV and/or panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or magnetic resonance imaging (MRI) scans throughout the trial.

ARM B: Patients receive one of the following standard chemotherapy regimens per the treating physician within 6 weeks of randomization: FOLFOXIRI (fluorouracil IV, oxaliplatin IV, irinotecan IV, and leucovorin IV), FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may receive capecitabine orally (PO) in substitution for fluorouracil at the discretion of the investigator and may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.

After completion of treatment, patients follow up every 3 months for 2 years and then every 6 months for an additional 3 years.

연구 유형

중재적

등록 (추정된)

408

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 빼는
        • University of Alabama at Birmingham Cancer Center
    • Arizona
      • Gilbert, Arizona, 미국, 85234
        • 모병
        • Banner MD Anderson Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 602-747-9738
        • 수석 연구원:
          • Rajesh Ramanathan
      • Phoenix, Arizona, 미국, 85006
        • 모병
        • Banner-University Medical Center Phoenix
        • 연락하다:
        • 수석 연구원:
          • Rajesh Ramanathan
      • Sun City, Arizona, 미국, 85351
        • 모병
        • Banner Boswell Medical Center
        • 연락하다:
        • 수석 연구원:
          • Rajesh Ramanathan
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • UCHealth University of Colorado Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 720-848-0650
        • 수석 연구원:
          • Alexis D. Leal
    • Florida
      • Aventura, Florida, 미국, 33180
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Aventura
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 954-461-2180
      • Coral Gables, Florida, 미국, 33146
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
      • Deerfield Beach, Florida, 미국, 33442
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
      • Hollywood, Florida, 미국, 33021
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Hollywood
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
      • Miami, Florida, 미국, 33176
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Kendall
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
      • Plantation, Florida, 미국, 33324
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Plantation
        • 수석 연구원:
          • Jashodeep Datta
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Emory University Hospital/Winship Cancer Institute
        • 연락하다:
          • Site Public Contact
          • 전화번호: 404-778-1868
        • 수석 연구원:
          • Olumide B. Gbolahan
      • Atlanta, Georgia, 미국, 30342
        • 모병
        • Emory Saint Joseph's Hospital
        • 수석 연구원:
          • Olumide B. Gbolahan
        • 연락하다:
          • Site Public Contact
          • 전화번호: 404-851-7115
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Ryan Merkow
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Northwestern University
        • 연락하다:
        • 수석 연구원:
          • Shishir K. Maithel
      • Chicago, Illinois, 미국, 60641
        • 모병
        • Northwestern Medicine Cancer Center Old Irving Park
        • 수석 연구원:
          • Shishir K. Maithel
        • 연락하다:
      • Shiloh, Illinois, 미국, 62269
        • 빼는
        • Memorial Hospital East
    • Indiana
      • Carmel, Indiana, 미국, 46032
        • 모병
        • IU Health North Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 317-278-5632
          • 이메일: iutrials@iu.edu
        • 수석 연구원:
          • Anita Turk
      • Indianapolis, Indiana, 미국, 46202
        • 모병
        • Indiana University/Melvin and Bren Simon Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 317-278-5632
          • 이메일: iutrials@iu.edu
        • 수석 연구원:
          • Anita Turk
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • 모병
        • University of Kentucky/Markey Cancer Center
        • 수석 연구원:
          • Michael J. Cavnar
        • 연락하다:
          • Site Public Contact
          • 전화번호: 859-257-3379
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • University of Michigan Rogel Cancer Center
        • 수석 연구원:
          • Benjamin D. Ferguson
        • 연락하다:
      • Grand Rapids, Michigan, 미국, 49503
        • 모병
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • 연락하다:
        • 수석 연구원:
          • Kathleen Y. Butler
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • University of Minnesota/Masonic Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 612-624-2620
        • 수석 연구원:
          • Ajay Prakash
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic in Rochester
        • 연락하다:
          • Site Public Contact
          • 전화번호: 855-776-0015
        • 수석 연구원:
          • Cornelius A. Thiels
    • Missouri
      • City of Saint Peters, Missouri, 미국, 63376
        • 빼는
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, 미국, 63141
        • 빼는
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, 미국, 63110
        • 빼는
        • Washington University School of Medicine
      • St Louis, Missouri, 미국, 63129
        • 빼는
        • Siteman Cancer Center-South County
      • St Louis, Missouri, 미국, 63136
        • 빼는
        • Siteman Cancer Center at Christian Hospital
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • 모병
        • Memorial Sloan Kettering Basking Ridge
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
      • Middletown, New Jersey, 미국, 07748
        • 모병
        • Memorial Sloan Kettering Monmouth
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
      • Montvale, New Jersey, 미국, 07645
        • 모병
        • Memorial Sloan Kettering Bergen
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
    • New York
      • Buffalo, New York, 미국, 14263
        • 모병
        • Roswell Park Cancer Institute
        • 수석 연구원:
          • Anuradha Krishnamurthy
        • 연락하다:
      • Commack, New York, 미국, 11725
        • 모병
        • Memorial Sloan Kettering Commack
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
      • East White Plains, New York, 미국, 10604
        • 모병
        • Memorial Sloan Kettering Westchester
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
      • New York, New York, 미국, 10029
        • 모병
        • Mount Sinai Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-824-7309
          • 이메일: CCTO@mssm.edu
        • 수석 연구원:
          • James O. Park
      • Uniondale, New York, 미국, 11553
        • 모병
        • Memorial Sloan Kettering Nassau
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Andrea Cercek
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke University Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 888-275-3853
        • 수석 연구원:
          • Hope E. Uronis
      • Raleigh, North Carolina, 미국, 27609
        • 모병
        • Duke Cancer Center Raleigh
        • 수석 연구원:
          • Hope E. Uronis
        • 연락하다:
      • Winston-Salem, North Carolina, 미국, 27157
        • 모병
        • Wake Forest University Health Sciences
        • 수석 연구원:
          • Perry Shen
        • 연락하다:
          • Site Public Contact
          • 전화번호: 336-713-6771
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • 모집하지 않고 적극적으로
        • Case Western Reserve University
      • Columbus, Ohio, 미국, 43210
        • 모병
        • Ohio State University Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Alex B. Blair
      • Youngstown, Ohio, 미국, 44501
        • 모병
        • Saint Elizabeth Youngstown Hospital
        • 연락하다:
        • 수석 연구원:
          • Howard M. Gross
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health and Science University
        • 연락하다:
          • Site Public Contact
          • 전화번호: 503-494-1080
          • 이메일: trials@ohsu.edu
        • 수석 연구원:
          • Skye C. Mayo
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103
        • 모병
        • Lehigh Valley Hospital-Cedar Crest
        • 연락하다:
        • 수석 연구원:
          • Tareq Al baghdadi
      • Erie, Pennsylvania, 미국, 16544
        • 모병
        • Saint Vincent Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 814-452-5000
        • 수석 연구원:
          • Patrick L. Wagner
      • Jefferson Hills, Pennsylvania, 미국, 15025
        • 모병
        • Jefferson Hospital
        • 연락하다:
        • 수석 연구원:
          • Patrick L. Wagner
      • Monroeville, Pennsylvania, 미국, 15146
        • 모병
        • Forbes Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 412-858-7746
        • 수석 연구원:
          • Patrick L. Wagner
      • Philadelphia, Pennsylvania, 미국, 19111
        • 모병
        • Fox Chase Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 215-728-4790
        • 수석 연구원:
          • Vanessa Wookey
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 모병
        • West Penn Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 412-578-5000
        • 수석 연구원:
          • Patrick L. Wagner
      • Pittsburgh, Pennsylvania, 미국, 15212
        • 모병
        • Allegheny General Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-284-2000
        • 수석 연구원:
          • Patrick L. Wagner
      • Wexford, Pennsylvania, 미국, 15090
        • 모병
        • Wexford Health and Wellness Pavilion
        • 연락하다:
        • 수석 연구원:
          • Patrick L. Wagner
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University/Ingram Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-811-8480
        • 수석 연구원:
          • Chandrasekhar Padmanabhan
    • Texas
      • Dallas, Texas, 미국, 75390
        • 모병
        • UT Southwestern/Simmons Cancer Center-Dallas
        • 연락하다:
        • 수석 연구원:
          • Adam C. Yopp
      • Dallas, Texas, 미국, 75235
      • Dallas, Texas, 미국, 75237
        • 모병
        • UT Southwestern Simmons Cancer Center - RedBird
        • 수석 연구원:
          • Adam C. Yopp
        • 연락하다:
      • Fort Worth, Texas, 미국, 76104
        • 모병
        • UT Southwestern/Simmons Cancer Center-Fort Worth
        • 연락하다:
        • 수석 연구원:
          • Adam C. Yopp
      • Richardson, Texas, 미국, 75080
        • 모병
        • UT Southwestern Clinical Center at Richardson/Plano
        • 연락하다:
        • 수석 연구원:
          • Adam C. Yopp
    • Wisconsin
      • Madison, Wisconsin, 미국, 53792
        • 모병
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • 연락하다:
        • 수석 연구원:
          • Patrick Varley
      • Madison, Wisconsin, 미국, 53718
        • 모병
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • 연락하다:
        • 수석 연구원:
          • Patrick Varley

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patient must be >= 18 years of age

  • Patient must have confirmed unresectable liver confined metastatic colorectal cancer (CRC).

    • Patient must not have radiographically or clinically evident extrahepatic disease (including but not limited to radiographically positive periportal lymph nodes).

      • NOTE: Patients found to have positive periportal nodes at the time of HAI placement can remain on study.

    • Patient may have calcified pulmonary nodules, and/or =< 5 indeterminate and stable (for a minimum of 3 months on chemotherapy) pulmonary nodules each measuring =< 6 mm in maximal axial dimension.

    • Patient's primary tumor may be in place

  • Patient must have received previous first-line chemotherapy that meets one of the following three criteria: a) have received at least 6 but no more than 12 cycles of first-line cytotoxic chemotherapy (where 1 cycle = 14 days) OR b) have received at least 4 but no more than 8 cycles of first-line cytotoxic chemotherapy (where 1 cycle = 21 days) OR c) have developed new colorectal liver metastases (CRLM) within 12 months of completing adjuvant systemic therapy for stage II-III colorectal cancer.

    • NOTE: First-line chemotherapy may have included any of the following regimens as listed in the National Comprehensive Cancer Network (NCCN) Guidelines: leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX) (or equivalent), leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan (FOLFIRI) (or equivalent), leucovorin calcium (calcium folinate), 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI), each with or without any of the following: bevacizumab, cetuximab, or panitumumab

  • Patient must have measurable disease

  • Patients who have disease progression, in the judgement of the treating multidisciplinary team, are not eligible.

    • This requirement does not apply to patients who developed new colorectal liver metastases within 12 months of completing adjuvant systemic therapy for stage II-III colorectal cancer

  • Patient must meet the following criteria for technical unresectability:

    • A margin-negative resection requires resection of three hepatic veins, both portal veins, or the retrohepatic vena cava OR a resection that leaves less than two adequately perfused and drained segments.
    • NOTE: Institutional multidisciplinary review is required to confirm unresectability and rule out radiographically positive extrahepatic disease.
    • NOTE: Patients who are deemed technically resectable but simultaneous biologically unresectable are not eligible.

  • Patient must undergo multiphase imaging of the chest, abdomen, and pelvis inclusive of CT and/or MRI angiography to confirm acceptable hepatic arterial anatomy for HAI and to rule out extrahepatic disease within 28 days prior to randomization.

    • NOTE: If the patient had remote liver-arterial phase imaging greater than 4 weeks from randomization, then only a single phase (portal venous) intravenous contrasted staging CT and/or MRI of the chest/abdomen/pelvis is required.

  • Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 and be clinically fit to undergo surgery as determined by the pre-operative evaluation.

  • Patient must not have a liver tumor burden exceeding 70% of total liver volume.

  • Patient must not have had prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 2 weeks prior to randomization).

  • Patient must not have had prior trans-arterial bland embolization, chemoembolization (TACE) or radioembolization (TARE).

  • Patient must not have had prior treatment with HAI/floxuridine (FUDR)

  • Patient must not have microsatellite instability-high (MSI-H) colorectal cancer.

  • Patient must not have CRLM that could be resected with 2-stage hepatectomy, including associating liver partition and portal vein ligation (ALPPS).

  • Patient must not have an active infection, serious or non-healing active wound, ulcer, or bone fracture.

  • Patient must not have any serious medical problems which would preclude receiving the protocol treatment or would interfere with the cooperation with the requirements of this trial.

  • Patient must not have cirrhosis and/or clinical or radiographic evidence of portal hypertension

  • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.

    • All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
    • A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study.

  • Leukocytes >= 3,000/mcL (obtained =< 28 days prior to protocol randomization)

  • Absolute neutrophil count (ANC) >= 1,500/mcL (obtained =< 28 days prior to protocol randomization)

  • Platelets >= 100,000/mcL (obtained =< 28 days prior to protocol randomization)

  • Total Bilirubin =< 1.5 mg/dL (obtained =< 28 days prior to protocol randomization)

  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to protocol randomization)

  • Creatinine =< 1.5 x institutional ULN OR creatinine clearance >= 50 mL/min calculated by the Cockcroft-Gault method (obtained =< 28 days prior to protocol randomization)

  • Calcium >= institutional lower limit of normal (LLN)

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial. Testing for HIV is not required for entry onto the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A (HAI, floxuridine, standard chemotherapy)

Patients undergo surgery to place the HAI pump within 6 weeks of randomization, followed by single SPECT/CT on study. Patients then receive floxuridine via the HAI pump within 12 weeks of randomization on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician within 16 weeks of randomization: FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV and/or panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.
의약품: Fluorouracil

Given IV

다른 이름들:
  • 5-플루라실
  • 플루라실
  • 5 플루오로우라실
  • 5 플루오로우라실룸
  • 5푸
  • 5-플루오로-2,4(1H,3H)-피리미딘디온
  • 5-플루오로우라실
  • 5-푸
  • 5FU
  • AccuSite
  • 카라크
  • 플루오로 우라실
  • 플루우라실
  • 플루라블라스틴
  • 플루라세딜
  • 플루릴
  • 플루로블라스틴
  • 리보플루오르
  • 로 2-9757호
  • Ro-2-9757
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
생물학적: Panitumumab

Given IV

다른 이름들:
  • ABX-EGF
  • ABX-EGF 단클론항체
  • ABX-EGF, 클론 E7.6.3
  • 모압 ABX-EGF
  • 단클론항체 ABX-EGF
  • Vectibix
  • E7.6.3
  • 인간 IgG2K 단클론항체
  • 모압 E7.6.3
  • 단클론항체 E7.6.3
의약품: Oxaliplatin

Given IV

다른 이름들:
  • 1-OHP
  • 다코틴
  • 닥플라
  • 엘록사틴
  • 아이 헹
  • 아이헝
  • 디아미노시클로헥산 옥살라토백금
  • JM-83
  • 옥살라토플라틴
  • 옥살라토백금
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • 엘플라트
  • JM 83
  • JM83
  • RP54780
  • SR 96669
의약품: Leucovorin

Given IV

다른 이름들:
  • 폴린산
생물학적: Cetuximab

Given IV

다른 이름들:
  • C225
  • 얼비툭스
  • IMC-C225
  • 세툭시맙 바이오시밀러 CDP-1
  • 세툭시맙 바이오시밀러 CMAB009
  • 세툭시맙 바이오시밀러 KL 140
  • 키메라 항-EGFR 단클론항체
  • 키메라 MoAb C225
  • 키메라 단클론항체 C225
  • C-225
  • Cetuximab-cetu
  • Cetuxa
  • ENZ 124
  • ENZ-124
  • ENZ124
의약품: Irinotecan

Given IV

의약품: Floxuridine

Given via HAI pump

다른 이름들:
  • 5-플루오로데옥시우리딘
  • 5-플루오로우라실 데옥시리보사이드
  • 5-FUdR
  • FDUR
  • 플록수리딘
  • 플루오로데옥시우리딘
  • 플루오로우리딘 데옥시리보스
  • 플루오루리딘 디옥시리보스
  • FUDR
  • WR-138720
  • 2'-데옥시-5-플루오로우리딘
  • 5-플루오로-2'-데옥시우리딘
  • WR 138720
  • WR138720
절차: Computed Tomography

Undergo SPECT/CT and/or CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Implantation

Undergo surgery to place the HAI pump

절차: Intrahepatic Infusion Procedure

Undergo HAI

다른 이름들:
  • 간동맥 주입
  • 하이
  • IHI
  • 간내 주입
절차: Single Photon Emission Computed Tomography

Undergo SPECT/CT

다른 이름들:
  • 성
  • 의료 영상, 단일 광자 방출 컴퓨터 단층 촬영
  • 단일 광자 방출 단층 촬영
  • 단일 광자 방출 컴퓨터 단층 촬영
  • SPECT
  • SPECT 이미징
  • 스펙트 스캔
  • SPET
  • 단층 촬영, 방출 계산, 단일 광자
  • 단일 광자 방출 계산
활성 비교기: Arm B (standard chemotherapy)

Patients receive one of the following standard chemotherapy regimens per the treating physician within 6 weeks of randomization: FOLFOXIRI IV, FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may receive capecitabine PO in substitution for fluorouracil at the discretion of the investigator and may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.
생물학적: Bevacizumab

Given IV

다른 이름들:
  • 아바스틴
  • ABP 215
  • 안티-VEGF
  • 항-VEGF 인간화 단클론항체
  • 항-VEGF 단클론항체 SIBP04
  • 항-VEGF rhuMAb
  • 베바시주맙
  • 베바시주맙 바이오시밀러 ABP 215
  • 베바시주맙 바이오시밀러 BEVZ92
  • 베바시주맙 바이오시밀러 BI 695502
  • 베바시주맙 바이오시밀러 CBT 124
  • 베바시주맙 바이오시밀러 CT-P16
  • 베바시주맙 바이오시밀러 FKB238
  • 베바시주맙 바이오시밀러 GB-222
  • 베바시주맙 바이오시밀러 HD204
  • 베바시주맙 바이오시밀러 HLX04
  • 베바시주맙 바이오시밀러 IBI305
  • 베바시주맙 바이오시밀러 LY01008
  • 베바시주맙 바이오시밀러 MIL60
  • 베바시주맙 바이오시밀러 음바시
  • 베바시주맙 바이오시밀러 MYL-1402O
  • 베바시주맙 바이오시밀러 QL 1101
  • 베바시주맙 바이오시밀러 RPH-001
  • 베바시주맙 바이오시밀러 SCT501
  • 베바시주맙 바이오시밀러 지라베브
  • 베바시주맙-awwb
  • 베바시주맙-bvzr
  • BP102
  • BP102 바이오시밀러
  • HD204
  • 면역글로불린 G1(Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF 경쇄, 이합체
  • 음바시
  • MYL-1402O
  • 재조합 인간화 항-VEGF 단클론 항체
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • 지라베프
  • 아베그라
  • QL1101
  • IBI305
  • 비바스다
  • 베바시주맙 바이오시밀러 QL1101
  • 박쥐1706
  • 박쥐 1706
  • BAT-1706
  • BAT1706 바이오시밀러
  • 베바시주맙 바이오시밀러 BAT1706
  • 베바시주맙-adcd
  • CT-P16
  • 베그젤마
  • 알림시스
  • ABP-215
  • ABP215
  • 아이빈티오
  • 베바시주맙-아이비
  • 베바시주맙-에퀴
  • 베바시주맙-말리
  • 베바시주맙-온베
  • CT P16
  • CTP16
  • 등가
  • 온베브지
  • 아브지비
  • 베바시주맙 바이오시밀러 MB02
  • 베바시주맙-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • 오야바스
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305
의약품: Fluorouracil

Given IV

다른 이름들:
  • 5-플루라실
  • 플루라실
  • 5 플루오로우라실
  • 5 플루오로우라실룸
  • 5푸
  • 5-플루오로-2,4(1H,3H)-피리미딘디온
  • 5-플루오로우라실
  • 5-푸
  • 5FU
  • AccuSite
  • 카라크
  • 플루오로 우라실
  • 플루우라실
  • 플루라블라스틴
  • 플루라세딜
  • 플루릴
  • 플루로블라스틴
  • 리보플루오르
  • 로 2-9757호
  • Ro-2-9757
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
의약품: Capecitabine

Given PO

다른 이름들:
  • 젤로다
  • Ro 09-1978/000
생물학적: Panitumumab

Given IV

다른 이름들:
  • ABX-EGF
  • ABX-EGF 단클론항체
  • ABX-EGF, 클론 E7.6.3
  • 모압 ABX-EGF
  • 단클론항체 ABX-EGF
  • Vectibix
  • E7.6.3
  • 인간 IgG2K 단클론항체
  • 모압 E7.6.3
  • 단클론항체 E7.6.3
의약품: Oxaliplatin

Given IV

다른 이름들:
  • 1-OHP
  • 다코틴
  • 닥플라
  • 엘록사틴
  • 아이 헹
  • 아이헝
  • 디아미노시클로헥산 옥살라토백금
  • JM-83
  • 옥살라토플라틴
  • 옥살라토백금
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • 엘플라트
  • JM 83
  • JM83
  • RP54780
  • SR 96669
의약품: Leucovorin

Given IV

다른 이름들:
  • 폴린산
생물학적: Cetuximab

Given IV

다른 이름들:
  • C225
  • 얼비툭스
  • IMC-C225
  • 세툭시맙 바이오시밀러 CDP-1
  • 세툭시맙 바이오시밀러 CMAB009
  • 세툭시맙 바이오시밀러 KL 140
  • 키메라 항-EGFR 단클론항체
  • 키메라 MoAb C225
  • 키메라 단클론항체 C225
  • C-225
  • Cetuximab-cetu
  • Cetuxa
  • ENZ 124
  • ENZ-124
  • ENZ124
의약품: Irinotecan

Given IV

절차: Computed Tomography

Undergo SPECT/CT and/or CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall survival (OS)
기간: From randomization to death from any cause, assessed up to 5 years

Patients still living will be censored at the date last known alive. OS will be evaluated using the Kaplan-Meier method, and arms will be compared via a stratified log rank test.
From randomization to death from any cause, assessed up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Progression free survival (PFS)
기간: From randomization to first observed disease progression at any site, or death from any cause, assessed up to 5 years

Patients still living without disease progression will be censored at the date of last disease assessment. Disease progression will be based on findings from surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months after randomization, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed similarly to OS, but with and without stratification for sensitivity.
From randomization to first observed disease progression at any site, or death from any cause, assessed up to 5 years
Hepatic PFS
기간: From randomization to first observed disease progression in the liver, or death from any cause, assessed up to 5 years

Patients still living without hepatic disease progression will be censored at the date of last disease assessment. Hepatic disease progression will be based on findings from surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months after randomization, defined by RECIST 1.1.
From randomization to first observed disease progression in the liver, or death from any cause, assessed up to 5 years
Extrahepatic-PFS
기간: From randomization to first observed disease progression outside of the liver, or death from any cause, assessed up to 5 years

Patients still living without extrahepatic disease progression will be censored at the date of last disease assessment. Extrahepatic disease progression will be based on findings from surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months after randomization, defined by RECIST 1.1.
From randomization to first observed disease progression outside of the liver, or death from any cause, assessed up to 5 years
Objective response rate
기간: Up to 5 years

Will assess hepatic disease burden specifically. Defined as the proportion of patients achieving complete or partial response by RECIST 1.1. Response will be based on surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months (+/- 2 weeks) from randomization. Arms will be compared via a Pearson chi-square test. All rates will be reported with exact binomial 95% confidence intervals.
Up to 5 years
Rate of conversion to resectable disease
기간: Up to 5 years

Defined as the proportion of patients who successfully convert from unresectable to resectable status and undergo R0/R1 resection/ablation. All rates will be reported with exact binomial 95% confidence intervals.
Up to 5 years
Intra-operative ineligibility rate
기간: Up to 5 years

Defined as the proportion of patients intended to receive hepatic arterial infusion that do not undergo pump implantation due to intraoperative detection of occult extrahepatic disease or unsuitable hepatic arterial anatomy. All rates will be reported with exact binomial 95% confidence intervals.
Up to 5 years
Incidence of adverse events
기간: Up to 5 years

Defined according to the Common Terminology Criteria for Adverse Events.
Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

ECOG-ACRIN Cancer Research Group

수사관

  • 수석 연구원: Michael Lidsky, ECOG-ACRIN Cancer Research Group

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 4월 10일

기본 완료 (추정된)

2029년 6월 30일

연구 완료 (추정된)

2029년 6월 30일

연구 등록 날짜

최초 제출

2023년 5월 9일

QC 기준을 충족하는 최초 제출

2023년 5월 9일

처음 게시됨 (실제)

2023년 5월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • EA2222
  • U10CA180820 (미국 NIH 보조금/계약)
  • EA2222 (기타 식별자: CTEP)
  • NCI-2023-02357 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • EA2222 (기타 식별자: ECOG-ACRIN Cancer Research Group)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다